Market closed
Tourmaline Bio/$TRML
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Tourmaline Bio
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
Ticker
$TRML
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
74
Website
Tourmaline Bio Metrics
BasicAdvanced
$641M
Market cap
-
P/E ratio
-$2.79
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$641M
52-week high
$48.31
52-week low
$12.12
Average daily volume
185K
Financial strength
Current ratio
40.333
Quick ratio
38.705
Long term debt to equity
0.02
Total debt to equity
0.09
Management effectiveness
Return on assets (TTM)
-23.82%
Return on equity (TTM)
-31.82%
Valuation
Price to book
2
Price to tangible book (TTM)
2
Price to free cash flow (TTM)
-8.71
Growth
Earnings per share change (TTM)
60.05%
What the Analysts think about Tourmaline Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Tourmaline Bio stock.
Tourmaline Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Tourmaline Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Tourmaline Bio News
AllArticlesVideos
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
GlobeNewsWire·2 days ago
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
GlobeNewsWire·4 weeks ago
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Tourmaline Bio stock?
Tourmaline Bio (TRML) has a market cap of $641M as of December 12, 2024.
What is the P/E ratio for Tourmaline Bio stock?
The price to earnings (P/E) ratio for Tourmaline Bio (TRML) stock is 0 as of December 12, 2024.
Does Tourmaline Bio stock pay dividends?
No, Tourmaline Bio (TRML) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next Tourmaline Bio dividend payment date?
Tourmaline Bio (TRML) stock does not pay dividends to its shareholders.
What is the beta indicator for Tourmaline Bio?
Tourmaline Bio (TRML) does not currently have a Beta indicator.